Market Overview

Wedbush Continues Outperform Rating On Regulus

Share:

In a report published Thursday, analyst Liana Moussatos of Wedbush Morgan maintained an Outperform rating on Regulus Therapeutics Inc. (NASDAQ: RGLS), with the price target set to $41.

In the report, Wedbush Morgan noted, "For Phase 2 RG-101/HCV testing, we prefer repeat dose monotherapy for simplicity but would like to see combinations with a potential best-in-class DAA in the pipeline and a separate arm with an approved DAA. In our view, the simplest treatment for HCV could be 1-2 shots of RG-101 monotherapy. However, we also view combinations with DAAs as promising. Due to RG-101's robust action--independent of genotype, treatment history and fibrosis stage--for combination treatment the company prefers pan-genotypic DAAs and has narrowed its choices to three. We would like to see one combination arm in the Phase 2 trial with Achillion's pipeline DAA given the rapid cure rate in 6-8 weeks instead of 12 weeks or more by the currently approved DAAs. We also see advantages to using an approved DAA, as well, in case a pipeline DAA is not on the market when RG-101 is potentially launched. The Phase 2 trial is expected to begin in Q2 with initial data release by year-end. We believe investors are likely to focus on monotherapy and potentially best-in-class combinations with rapid cures across genotypes."

"We anticipate the choice of DAA for RG-101 Phase 2 combination arms could provide near-term upside for the stock. The choice of DAA(s) for the combo therapy could also suggest which pharma becomes a partner and we anticipate a lucrative arrangement for Regulus," Moussatos wrote.

Latest Ratings for RGLS

DateFirmActionFromTo
Sep 2019Initiates Coverage OnBuy
Mar 2019MaintainsMarket PerformMarket Perform
Jul 2018DowngradesOutperformNeutral

View More Analyst Ratings for RGLS
View the Latest Analyst Ratings

Posted-In: Wedbush MorganAnalyst Color Analyst Ratings

 

Related Articles (RGLS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MUCascendReiterates65.0
ALDRCanaccord GenuityDowngrades20.0
LEGHLake StreetInitiates Coverage On21.0
CHUGoldman SachsUpgrades13.2
STZBMO CapitalMaintains230.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Nomura Recap Of Stocks To Look Out For

Hatteras Financial PT Cut By MLV